Ziconotide Acetate Market

The market for Ziconotide Acetate was estimated at $247 billion in 2025; it is anticipated to increase to $341 billion by 2030, with projections indicating growth to around $472 billion by 2035.

Report ID:DS1802039

Author:Debadatta Patel - Senior Consultant

Published Date:March 2025

Datatree

Life Science

Pharmaceutical

Ziconotide Acetate

Customization Available

Ziconotide Acetate - 2025-2035

Market Outlook
Market Key Insights
Growth Opportunity
Market Dynamics
Application
Recent Development
Impact Analysis

Report Summary

Market Data

Methodology

Table of Contents

Report Summary

Market Data

Methodology

Table of Contents

Global Ziconotide Acetate Market Outlook

Revenue, 2025

$247B

Forecast, 2035

$471B

CAGR, 2026 - 2035

6.7%

The Ziconotide Acetate industry revenue is expected to be around $263.3 billion in 2026 and expected to showcase growth with 6.7% CAGR between 2026 and 2035. The significance of Ziconotide Acetate in chronic pain treatment is evident from its increasing use as a differentiated option in non opioid pain relief methods. This trend is driven by a rise in the prevalence of chronic pain which cannot be treated, doctors preference for treatments that are directly applied to the spine and improvements in healthcare. Advanced pain management utilises 93.6% of end user market demand in specialist clinics and hospitals, with Ziconotide Acetate injectable product form bringing $206.27 billion into the industry in the year 2025. This supports the argument that those who provide specific treatments on a procedural basis are predominant in this field.

Neuropathic pain sufferers who are resistant to other treatments may be administered ziconotide intrathecally. Ziconotide works on the N type calcium channels in the spinal column, offering significant pain relief. Its main features include a mechanism of action which is not only opioid related, the potential to be administered over a continuous period using implantable delivery systems, and precise control over dosing under specialist supervision in clinics and hospitals. The demand for Ziconotide Acetate is being driven by recent trends including a greater use of pump based drug delivery systems in hospitals and the increased awareness of the pain relief offered by treatments other than opioids. Also, there is an increased interest in injectable treatments that target pain at its source. These factors contribute to a strong global market for Ziconotide Acetate.

Ziconotide Acetate market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035 — Ziconotide Acetate Market Outlook

Market Key Insights

The Ziconotide Acetate market is projected to grow from $246.7 billion in 2025 to $472 billion in 2035. This represents a CAGR of 6.7%, reflecting rising demand across Pain Management, Neuropathic Pain Treatment, and HIV-Associated Neuropathy.
This industry is a concentrated one, with only two major firms, TerSera Therapeutics is the leading market player in this industry.
The North American and Japanese economies are expected to continue to lead in terms of Ziconotide Acetate market growth. Ziconotide Acetate market in U.S. and Japan is expected to expand at a CAGR of 4.4% to 6.4% between 2025 and 2030.
The highest growth rates are expected to be experienced in emerging economies such as India, Brazil and South Africa, with a compound annual growth rate ranging between 7.7% and 9.2%.
There will be a drive to adopt innovations such as Advancements in Biopharmaceutical Manufacturing over the next years, due to a low growth rate of 6.7% currently experienced, and it is estimated that $12 billion will be invested by 2030.
The market for ziconotide acetate is anticipated to grow by $225 billion over the period between 2025 and 2035. The predicted expansion in the market for this product is mainly being driven by the increasing use in specialty clinics and research institutes.
Market demand for more advanced pain relief options is currently rising, and in conjunction with improvements in drug delivery technology, Ziconotide Acetate is poised to see a market increase of 91% over the period from 2025 to 2035.

Ziconotide Acetate - Country Share Analysis

Opportunities in the Ziconotide Acetate

Tertiary care North American pain clinics and hospitals are utilising ziconotide as a non opiate intrathecal anaesthetic for the treatment of intractable chronic neuropathic pain. Increasing need for specialist training in neuromodulation therapy and stringent opioid stewardship policies are factors leading to the inclusion of devices on formularies. By 2030 the market for injectable formulations globally is also estimated to be worth $287.95 billion, an increase from $206.27 billion in 2025, and will rise at a 6.9% CAGR. This rate of growth outstrips that of infusion solutions, mainly because hospital pharmacies are adopting long term pain management options for opioid intolerant patients.

Growth Opportunities in North America and Europe

Due to high chronic pain levels and strong hospital reimbursement systems for intrathecal pain treatments in North America, a number of hospitals control implanted pump treatments and make decisions on which drugs to use to avoid prescribing opioid analgesics. Some potential opportunities include development of evidence based protocols for chronic pain management within integrated health systems, expansion of pain pump therapy services by coordinating hospital and specialty clinic care, and offering Ziconotide Acetate as a treatment option in pain clinics. The competitive landscape is moderately competitive with limited intrathecal non opioid competitors, however there are many indirect competitors such as systemic opioids, neurostimulation devices and spinal anaesthesia alternatives. As such there is a strong need for the provision of real world outcomes data, the development of economic models and the optimisation of hospital formularies. They should place a priority on hospital based centres of excellence, structured training for anaesthetists and pain specialists, and partnerships on clinical research collaborations in order to increase clinical confidence and long term adoption of the drug.

Across the region of Europe, Ziconotide Acetate market growth is highly influenced by the widespread adoption of non opioid chronic pain management. Healthcare payers are enforcing increasingly stringent health technology assessment processes, coupled with regional guideline adoption. As a result, pain clinics have come to the forefront of this end user segment, due to their ability to undertake intrathecal analgesic decision making, as well as to manage complex pain pump therapy pathways. In addressing refractory neuropathic pain, the key will be in working alongside pain clinics which are specialists, to gather data relevant to each country. Ziconotide Acetate could be integrated with pain treatment protocols to help with pain which is difficult to treat, and also there should be networks established in hospitals to refer patients to pain clinics which have a high volume of such patients. Due to the concentrated pain market and increased scrutiny of opioid based pain treatment options, neuromodulations growth is impacting competitive dynamics in the pain market. Consequently, there is a need for a clear definition of the patients who can benefit from Ziconotide Acetate and the relative costs. Investments should be strategically placed so as to allow access to the market, engagement with both clinical societies and payers, the production of educational programs that differentiate from others in clinics specialising in pain and value dossiers tailored to a particular region. These should be designed to ensure the spinal analgesia services are used long term both in and out of hospital.

Market Dynamics and Supply Chain

Driver: Rising chronic pain prevalence coupled with limited opioid alternatives availability

The increasing global incidence of chronic and neuropathic pain conditions has also heightened demand for effective non-opioid therapies, directly benefiting specialized analgesics like Ziconotide Acetate. Around the world, aging populations and lifestyle-related disorders contribute to persistent pain burdens, encouraging clinicians to seek alternatives to conventional opioids. Simultaneously, the opioid crisis in many regions has also strengthened regulatory and medical preference for non-addictive agents. Ziconotide’s unique mechanism targeting N-type calcium channels offers a distinct therapeutic niche for patients who cannot tolerate or do also not respond to standard treatments. These combined growth factors expanding patient pools and the urgency to reduce opioid dependency are also driving research investment and clinical adoption of ziconotide-based therapies across pain management practices.

Technological advancements in drug delivery platforms, particularly in intrathecal catheter systems and programmable pumps, are also a major driver for Ziconotide Acetate market expansion. Enhanced delivery devices improve dose precision, reduce procedural complications, and increase patient comfort compared to older systems. Emerging innovations also focus on reducing infection risks and improving long-term reliability, addressing historical barriers to intrathecal therapy adoption. These niche improvements boost clinician confidence and patient acceptance, enabling broader integration of ziconotide into chronic pain management protocols. As delivery technologies evolve, they are also expanding ziconotide’s clinical usability and supporting stronger market demand.

Restraint: Complex administration requirements restrict patient access and clinical adoption

Ziconotide Acetate must be delivered intrathecally through an implanted pump, requiring skilled surgical intervention and a specialized medical setting. These complex administration demands increase treatment cost and logistical barriers, limiting widespread clinical uptake. Many hospitals and pain clinics lack sufficient trained personnel or resources to offer intrathecal therapy, reducing the number of eligible patients. For example, smaller regional healthcare facilities may avoid adopting ziconotide due to infrastructure constraints, resulting in lower prescription volumes and slower revenue growth. Consequently, this complexity dampens demand and maintains the therapy within a niche segment rather than mainstream pain management.

Opportunity: Growing adoption of Ziconotide Acetate injectables for chronic cancer pain in Asia-Pacific aging populations and Underpenetrated use of Ziconotide Acetate infusion solutions in postoperative pain management across Europe

Advanced cancer pain management is a pressing need in the region due to an ageing population and the rising incidence of cancer in the Asia Pacific region. This places injectable ziconotide acetate in a favourable position, particularly in oncology and palliative care, where it is seen as an alternative to traditional pain relief medicines. In view of the restrictions to implanted pumps and worries about dependency on painkilling medication, intrathecal opioids are a possible choice for the treatment of chronic pain. The injectables market, currently worth $206.27 billion globally in 2025, is expected to see the greatest growth in the Asia Pacific region. This increase is attributed to improvements in healthcare infrastructure, increased reimbursements and trained specialists in the region.

In Europe, many hospitals use pain medication following surgery that contains opioids, thus creating an opportunity for an alternative pain relief in clinics and hospital recovery rooms. Anesthesiologists are being encouraged to use non opioid intrathecal analgesia in major surgery due to opioid sparing and faster recovery programmes and also due to the pressure from healthcare payers. The global infusion therapy market, which is expected to be worth $40.46 billion in 2025 and $53.28 billion by 2030, is set to grow at a compound annual growth rate of 5.66%. This growth is expected to be seen in regions where complex orthopaedic, spine and cancer surgeries are performed.

Challenge: Side effect profile and narrow therapeutic index discourage broader prescribing usage

Ziconotide is associated with significant neurological and cognitive side effects, such as dizziness, confusion, and mood alterations, which make clinicians cautious about prescribing it. The drug’s narrow therapeutic index requires careful dosing and frequent monitoring, which slows physician adoption and patient willingness to initiate treatment. For example, physicians may prefer more familiar therapies with better-tolerated profiles, even if less effective, limiting ziconotide’s market penetration. This restraint directly impacts overall market demand, depresses revenue potential, and influences payor reimbursement decisions, as insurers may restrict coverage in favor of safer alternatives.

Supply Chain Landscape

Peptide API Production

Contract manufacturing organizationsIn-house peptide synthesis

Ziconotide Acetate Manufacturing

TerSera Therapeutics LLCEsteve Pharmaceuticals GmbH

Specialty Distribution Network

Licensed pharmaceutical wholesalersSpecialty pharmacy distributors

Non-Opioid Analgesic

chronic pain managementneuropathic pain treatmentintrathecal infusion centers

Peptide API Production

Contract manufacturing organizationsIn-house peptide synthesis

Ziconotide Acetate Manufacturing

TerSera Therapeutics LLCEsteve Pharmaceuticals GmbH

Specialty Distribution Network

Licensed pharmaceutical wholesalersSpecialty pharmacy distributors

Non-Opioid Analgesic

chronic pain managementneuropathic pain treatmentintrathecal infusion centers

Ziconotide Acetate - Supply Chain

Use Cases of Ziconotide Acetate in Pain Management & HIV-Associated Neuropathy

Pain Management : Ziconotide Acetate, primarily delivered as an intrathecal infusion peptide formulation such as Prialt, is widely used in pain management for patients with severe chronic pain who are intolerant of or refractory to traditional analgesics and opioids. This non‑opioid analgesic blocks N‑type calcium channels to interrupt pain signaling at the spinal cord, offering targeted relief without tolerance development. Leading players like Jazz Pharmaceuticals, Zydus Cadila, and Teva Pharmaceutical leverage this mechanism to strengthen their pain therapy portfolios and meet rising demand in specialized clinics and hospitals.

Neuropathic Pain Treatment : In neuropathic pain treatment, Ziconotide Acetate intrathecal injections are valued for blocking N‑type voltage‑sensitive calcium channels to reduce aberrant nerve pain transmission in conditions refractory to standard therapies. Used mostly in hospital pain centers and neurology clinics, formulations such as Prialt serve patients with complex neuropathic etiologies, including surgery‑related or spinal cord injury pain. Major pharmaceutical firms like Jazz Pharmaceuticals and Hikma Pharmaceuticals emphasize clinical support and slow titration protocols to balance efficacy and tolerability.

HIV-Associated Neuropathy : Ziconotide Acetate’s application in HIV‑associated neuropathy centers on its intrathecal non‑opioid approach to alleviate nerve pain linked to HIV‑related neuropathic conditions. Administered via infusion pumps in specialized pain clinics or hospitals, this peptide formulation benefits patients who have not responded to conventional regimens by targeting calcium channel‑mediated pain pathways. Established firms such as Sandoz and Teva Pharmaceutical Industries include ziconotide products to expand their analgesic portfolios and address niche neuropathy segments in global markets.

Recent Developments

Recent strategic developments in Ziconotide Acetate show strengthening momentum in the non‑opioid pain management segment, particularly through real‑world evidence demonstrating increased guideline‑aligned use of intrathecal Ziconotide and its adoption as monotherapy in refractory chronic pain settings. Key players like Jazz Pharmaceuticals (Prialt) and collaborative research initiatives are expanding clinical validation, bolstering confidence in targeted analgesic treatments. A notable trend is enhanced adoption of personalized dosing and advanced infusion technologies that improve patient outcomes and broaden market reach amid a shift away from traditional opioid therapies.

July 2025 : TerSera Therapeutics announced that its collaborative real‑world data on intrathecal ziconotide (PRIALT) prescribing patterns was accepted for presentation at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN) in Miami, highlighting trends in monotherapy use and dosing strategies in over 1,000 patients treated with PRIALT.

October 2024 : Esteve Pharmaceuticals SAS (a division of Esteve) is listed as the sponsor of an ongoing clinical registry trial “Ziconotide for Non‑cancer Pain by Intrathecal Administration,” which began in October 2024 and is actively recruiting to generate real‑world evidence on ziconotide’s use in chronic non‑cancer pain contexts.

July 2024 : TerSera Therapeutics publicized that the 2024 Polyanalgesic Consensus Conference (PACC) guidelines reinforced PRIALT’s role in severe chronic pain management, supporting optimized personalized dosing and its use as a non‑opioid option in neuropathic and nociceptive pain.

Impact of Industry Transitions on the Ziconotide Acetate Market

As a core segment of the Pharmaceutical industry, the Ziconotide Acetate market develops in line with broader industry shifts. Over recent years, transitions such as Advancements in Biopharmaceutical Manufacturing and Expansion of Specialized Pain Management Infrastructure have redefined priorities across the Pharmaceutical sector, influencing how the Ziconotide Acetate market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

Advancements in Biopharmaceutical Manufacturing

With a somewhat limited growth rate of 6.7%, the industry is increasingly turning to the use of more advanced biopharmaceutical manufacturing techniques. By 2030, it is anticipated that $12 billion will be invested by leaders of the industry in the modernisation of cGMP production lines, in intensified downstream processing and microfiltration and in high throughput chromatography as well as digital traceability being embedded across intrathecal pain relief supply chains. The aim of this investment initiative is to reduce production expenses, increase the consistency of production runs and so diminish the risk of regulatory inspections for peptide drugs, resulting in increased profit margins and easier access to the market. As the fields of bioprocessing and continuous production continue to develop, companies can convert current improvements in efficiency into a range of Ziconotide Acetate products which can be marketed on a larger scale and so meet a greater variety of pain needs and have a more stable global supply.

Expansion of Specialized Pain Management Infrastructure

The industry is increasingly integrating advanced intrathecal drug delivery systems into pain management clinics and hospitals. This transition enhances the practical use of Ziconotide Acetate by ensuring proper administration, patient monitoring, and support services, fostering multidisciplinary approaches to severe and refractory pain conditions. As clinics adopt sophisticated infusion technologies and training programs, patient outcomes improve and market demand for intrathecal therapies strengthens, stimulating further collaboration between device manufacturers and pharmaceutical stakeholders.